RxDoctor Payments Data

Mark Brown, MD

Internal Medicine · Phoenixville, PANPI 1467491050

Payments from drug & device makers

$7,482in general payments, 2019–2025

Across 486 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Johnson & Johnson$956
  • AbbVie$602
  • AstraZeneca$531
  • GSK$445
  • Pfizer$433
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,43499%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,482 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$101,418
Medicare patients
536
Services billed
1,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$105,797
GlyxambiEmpagliflozin/Linagliptin74$96,480
XareltoRivaroxaban76$86,752
JanuviaSitagliptin Phosphate61$67,961
JardianceEmpagliflozin48$61,260
TradjentaLinagliptin21$32,028
MyrbetriqMirabegron30$20,596
CreonLipase/Protease/Amylase12$16,760
Breo ElliptaFluticasone/Vilanterol22$15,115
Atorvastatin Calcium966$12,061
FarxigaDapagliflozin Propanediol12$11,796
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide342$8,819
InvokametCanagliflozin/Metformin Hcl12$6,755
Levothyroxine Sodium537$6,395
Rosuvastatin Calcium376$6,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimGlyxambi, Jardiance, Tradjenta$395$189,768143 claims
PfizerEliquis$433$105,797100 claims
Johnson & JohnsonXarelto, Invokamet$956$93,50888 claims
MerckJanuvia$287$67,96161 claims
Astellas Pharma US IncMyrbetriq$187$20,59630 claims
AbbVieCreon, Synthroid$602$18,98436 claims
GSKBreo Ellipta$445$15,11522 claims
AstraZenecaFarxiga$531$11,79612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Phoenixville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →